Daiichi Sankyo Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DAIICHI SANKYO INC, and when can generic versions of DAIICHI SANKYO INC drugs launch?
DAIICHI SANKYO INC has three approved drugs.
There are twenty-five US patents protecting DAIICHI SANKYO INC drugs.
There are three hundred and nineteen patent family members on DAIICHI SANKYO INC drugs in forty-five countries and seventeen supplementary protection certificates in fifteen countries.
Summary for Daiichi Sankyo Inc
International Patents: | 319 |
US Patents: | 25 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 3 |
Drugs and US Patents for Daiichi Sankyo Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-002 | Oct 14, 2022 | RX | Yes | No | 9,169,250 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-002 | Jan 8, 2015 | RX | Yes | No | 7,365,205 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 8,129,374 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-002 | Jul 20, 2023 | RX | Yes | Yes | 8,883,783 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-002 | Jul 20, 2023 | RX | Yes | Yes | 9,675,549 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for Daiichi Sankyo Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2447779 | ⤷ Try a Trial |
European Patent Office | 2827904 | ⤷ Try a Trial |
Poland | 2001892 | ⤷ Try a Trial |
Croatia | P20200255 | ⤷ Try a Trial |
Mexico | 2008011684 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Sankyo Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2140867 | PA2018005,C2140867 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
1405852 | 2015/045 | Ireland | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATIC THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
1405852 | C01405852/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN; REGISTRATION NO/DATE: SWISSMEDIC 65149 31.03.2015 |
1405852 | 612 | Finland | ⤷ Try a Trial | |
1405852 | 1590052-5 | Sweden | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE.; REG. NO/DATE: EU/1/15/993/001-028 20150623 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.